Oral cancer
Also known as: mouth cancer · oral cavity cancer · oral squamous cell carcinoma
Free to read — no account needed. Sign in only to bookmark this disease and track your study progress.
Evaluation of Potentially Malignant Disorders in the Oral Cavity - ADA Living Clinical Practice Guideline
American Dental Association (ADA), with the Center for Integrative Global Oral Health, University of Pennsylvania School of Dental Medicine · 2026 · Living guideline, 2026 update
A living ADA guideline on the use of adjunct tools when evaluating oral mucosal lesions that may be potentially malignant. The 2026 update revises the 2017 guideline and is being released in parts covering cytology, vital staining, light-based adjuncts, and salivary tests. Throughout, biopsy is described as the reference standard for diagnosis, with adjuncts positioned as triage aids.
- The 2026 living update replaces the ADA's 2017 guideline on evaluating potentially malignant disorders in the oral cavity. source
- Four adjunct categories are addressed - cytology, vital staining, light-based adjuncts and salivary tests - with the salivary component released later. source
- Biopsy remains the stated reference standard for diagnosing oral potentially malignant disorders and oral squamous cell carcinoma. source
Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
European Head and Neck Society (EHNS), European Society for Medical Oncology (ESMO) and European Society for Radiotherapy and Oncology (ESTRO) · 2020 · 2020 clinical practice guideline
The joint European oncology guideline for squamous cell carcinoma of the head and neck, including the oral cavity. It covers clinical and pathological diagnosis, staging and risk assessment, treatment across surgical, radiotherapy and systemic modalities, and follow-up. It is the reference European document for managing oral cancer once malignancy is established, as distinct from dental-society guidance on lesion screening and triage.
- Jointly issued by EHNS, ESMO and ESTRO and published in Annals of Oncology in 2020. source
- Scope spans diagnosis, staging and risk assessment, treatment and follow-up for oral cavity, larynx, oropharynx and hypopharynx tumours. source
- An ESMO guideline page for this document is maintained on the society's own website. source
US vs EU key differences
- The documents sit at different points in the pathway: the ADA guideline covers dental-office evaluation of oral potentially malignant disorders, with biopsy or specialist referral as the reference standard, while the European guideline begins at diagnosed squamous cell carcinoma and covers staging, treatment and follow-up. source
- The ADA guideline is a 'living' document published in parts, covering cytology, vital staining and light-based adjuncts with a salivary-test section due in 2026, whereas the EHNS-ESMO-ESTRO guideline is a fixed 2020 publication. source
- The European guideline drives management from UICC TNM 8th-edition staging and biomarker status, strongly recommending p16 immunohistochemistry for all newly diagnosed oropharyngeal squamous cell carcinoma with a confirmatory HPV test if p16 is positive; the ADA guideline stops at biopsy or referral and does not address staging or oncological treatment. source
What changed recently
- US2017 guideline → Living guideline, 2026 update2026-01-01
The 2026 living guideline updates the ADA's 2017 statement on potentially malignant oral disorders and now conditionally recommends against vital staining adjuncts such as toluidine blue for deciding on biopsy or referral, warning they can prompt unnecessary procedures or delay diagnosis. Conventional visual and tactile examination plus scalpel or punch biopsy with histopathology is reaffirmed as the standard pathway.
See the full update feed for changes across every system.